Guidant Corporation Announces ADVANCENT Registry Phase 2

Strategic Insights -

Guidant Corporation, a leader in the treatment of cardiac and vascular disease, has announced the next phase of its ADVANCENT national registry to study left ventricular dysfunction (LVD). The ADVANCENT 'in Practice' edition will focus on helping physicians identify patients who could benefit from advanced treatment options by tracking standard cardiac measurements such as blood pressure, cholesterol, and ejection fraction. This new phase aims to close the gaps in care identified in the initial registry, which highlighted disparities in treatment between men and women, as well as differences in age and ethnicity.

Key Takeaways:

  • The ADVANCENT 'in Practice' edition will track standard cardiac measurements such as blood pressure, cholesterol, and ejection fraction to help identify patients who could benefit from advanced treatment options.
  • The registry will focus on helping physicians close identified gaps in care, particularly for traditionally underserved populations.
  • The ADVANCENT national registry has identified disparities in treatment between men and women, as well as differences in age and ethnicity.
  • Over 100 centers and 25,000 enrolled patients took part in the initial ADVANCENT registry.
  • The registry found that women with indications for treatment received cardiac resynchronization therapy systems or implantable cardioverter defibrillators one-third of the time, while men received therapy half of the time.
  • The ADVANCENT Scientific Steering Committee provided guidance for the registry, and centers that participated are being congratulated by Guidant Corporation.
  • The 'in Practice' edition will help to affect change in cardiology practices nationwide by providing registry data to physicians.

Statistics:

  • Over 25,000 patients were enrolled in the initial ADVANCENT registry.
  • The registry found that women with indications for treatment received cardiac resynchronization therapy systems or implantable cardioverter defibrillators one-third of the time.
  • Men received cardiac resynchronization therapy systems or implantable cardioverter defibrillators half of the time.
  • More than 100 centers took part in the initial ADVANCENT registry.
  • The ADVANCENT 'in Practice' edition will track cardiac measurements for patients with left ventricular dysfunction (LVD) with an ejection fraction of 40 percent or less.

Sources:

  • "Guidant Corporation Announces ADVANCENT Registry Phase 2." Guidant Corporation, 8th Annual Scientific Meeting of the Heart Failure Society of America.
  • Joseph Smith, M.D., Ph.D., FACC, chief medical officer, Cardiac Rhythm Management, Guidant Corporation.
  • Reynolds Delgado, M.D., director, The Institute for Heart Failure Treatment and Research at The Texas Heart Institute and a member of the ADVANCENT Scientific Steering Committee.